Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Overview of attention for article published in New England Journal of Medicine, August 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 31 news outlets
blogs: 5 blogs
policy: 1 policy source
twitter: 364 X users
facebook: 1 Facebook page
wikipedia: 4 Wikipedia pages

reddit: 2 Redditors
f1000: 1 research highlight platform
video: 1 YouTube creator
guideline: 9 clinical guideline sources
podcasts: 5 podcasts

Readers on

mendeley: 246 Mendeley

So far, Altmetric has seen 504 X posts from 364 X users, with an upper bound of 2,384,014 followers.

RT @ErikSosa2018: @JuanMaNvz @valeriaram1993 @nagriar5 @DiegOnco5 @UrielF17909 @malenyrm91 @AJobDS @jaimecalfel @ClauAlmeZ @carlooz21 @Sola…

@JuanMaNvz @valeriaram1993 @nagriar5 @DiegOnco5 @UrielF17909 @malenyrm91 @AJobDS @jaimecalfel @ClauAlmeZ @carlooz21 @SolaresL @JenPlazaV De acuerdo al estudio @DrChoueiri et al. KEYNOTE-564 https://t.co/ViaEjeg2C9 Que riesgo es nuestra paciente para adyu…

RT @DrChoueiri: 4/ Pts were randomized 1:1 to receive pembrolizumab 200mg Q3W for 1 yr or placebo Primary endpoint: DFS (investigator) - m…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 500 additional X posts.